Back to results
US 2003/0149043 A1Published application
N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia
AssigneePfizer Inc.
InventorsErnest S. Hamanaka, Angel Guzman-Perez, Christian J. Mularski, Roger B. Ruggeri, Ronald T. Wester
Life of this patent
Estimating the term…
Abstract
NHE-1 inhibitors, methods of using such NHE-1 inhibitors and pharmaceutical compositions containing such NHE-1 inhibitors. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.
Claims173
A compound having the Formula I
- 25
- a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug wherein
- Z is carbon connected and is a five-membered, diaza, diunsaturated ring having two contiguous nitrogens, said ring optionally mono-, di-, or tri-substituted with up to three substituents independently selected from R1, R2 and R3;
- or
- Z is carbon connected and is a five-membered, triaza, diunsaturated ring, said ring optionally mono- or di-substituted with up to two substituents independently selected from R4 and R5;
- wherein R1, R2, R3, R4 and R5 are each independently hydrogen, hydroxy(C1-C4)alkyl, (C1-C4)alkyl, (C1-C4)alkylthio, (C3-C4)cycloalkyl, (C3-C7)cycloalkyl(C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkoxy(C1-C4)alkyl, mono-N- or di-N,N-(C1-C4)alkylcarbamoyl, M or M(C1-C4)alkyl, any of said previous (C1-C4)alkyl moieties optionally having from one to nine fluorines;
- said (C1-C4)alkyl or (C3-C4)cycloalkyl optionally mono-or di-substituted independently with hydroxy, (C1-C4)alkoxy, (C1-C4)alklthio, (C1-C4)alkylsulfinyl, (C1-C4)alkylsulfonyl, (C1-C4)alkyl, mono-N- or di-N,N-(C1-C4)alkylcarbamoyl or mono-N- or di-N,N-(C1-C4)alkylaminosulfonyl;
- and said (C3-C4)cycloalkyl optionally having from one to seven fluorines;
- wherein M is a partially saturated, fully saturated or fully unsaturated five to eight membered ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen, or, a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;
- said M is optionally substituted, on one ring if the moiety is monocyclic, or one or both rings if the moiety is bicyclic, on carbon or nitrogen with up to three substituents independently selected from R6, R7 and R8, wherein one of R6, R7 and R8 is optionally a partially saturated, fully saturated, or fully unsaturated three to seven membered ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen optionally substituted with (C1-C4)alkyl and additionally R6, R7 and R8 are optionally hydroxy, nitro, halo, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, (C1-C4)alkyl, formyl, (C1-C4)alkanoyl, (C1-C4)alkanoyloxy, (C1-C4)alkanoylamino, (C1-C4)alkoxycarbonylamino, sulfonamido, (C1-C4)alkylsulfonamido, amino, mono-N- or di-N,N-(C1-C4)alkylamino, carbamoyl, mono-N- or di-N,N-(C1-C4)alkylcarbamoyl, cyano, thiol, (C1-C4)alkylthio, (C1-C4)alkylsulfinyl, (C1-C4)alkylsulfonyl, mono-N- or di-N,N-(C1-C4)alkylaminosulfonyl, (C2-C4)alkenyl, (C2-C4)alkynyl or (C5-C7)cycloalkenyl,
- wherein said (C1-C4)alkoxy, (C1-C4)alkyl, (C1-C7)alkanoyl, (C1-C4)alkylthio, mono-N- or di-N,N-(C1-C4)alkylamino or (C3-C7)cycloalkyl R6, R7 and R8 substituents are optionally mono- substituted independently with hydroxy, (C1-C4)alkoxycarbonyl, (C3-C7)cycloalkyl, (C1-C4)alkanoyl, (C1-C4)alkanoylamino, (C1-C4)alkanoyloxy, (C1-C4)alkoxycarbonylamino, sulfonamido, (C1-C4)alkylsulfonamido, amino, mono-N- or di-N,N-(C1-C4)alkylamino, carbamoyl, mono-N- or di-N,N-(C1-C4)alkylcarbamoyl, cyano, thiol, nitro, (C1-C4)alkylthio, (C1-C4)alkylsulfinyl, (C1-C4)alkylsulfonyl or mono-N- or di-N,N-(C1-C4)alkylaminosulfonyl or optionally substituted with one to nine fluorines.
8 more elements
A compound, wherein said compound is
- 5-Methyl-2-(5-quinolinyl)-2H-1,2,3-triazole-4-carboxylic acid,
- 5-Methyl-2-(5-isoquinolinyl)-2H-1,2,3-triazole-4-carboxylic acid,
- 2-(1 -Naphthalenyl)-5-methyl-2H-1,2,3-triazole4-carboxylic acid,
- Ethyl 5-cyclopropyl-1-(2-trifluoromethylphenyl)-1H-pyrazole-4-carboxylate,
- Ethyl 5-methyl-1-(6-quinolinyl)-1H-pyrazole-4-carboxylate,
- Ethyl 5-methyl-1-naphthalenyl-1H-pyrazole-4-carboxylate,
- Ethyl 5-cyclopropyl-1-(quinolin-8-yl)-1H-pyrazole-4-carboxylate,
- Ethyl 5-cyclopropyl-1-(quinolin-5-yl)-1H-pyrazole-4-carboxylate,
- Methyl 5-ethyl-1-(quinolin-5-yl)-1H-pyrazole-4-carboxylate,
- n-Butyl 1 -(isoquinolin-5-yl)-3-methyl-1H-pyrazole-4-carboxylate,
- 5-Methyl-1-(6-quinolinyl)-1H-pyrazole-4-carboxylic acid,
- 5-Methyl-1-naphthalenyl-1H-pyrazole-4-carboxylic acid,
- 5-Cyclopropyl-1-(quinolin-8-yl)-1H-pyrazole-4-carboxylic acid,
- 5-Cyclopropyl-1-(2-trifluoromethylphenyl)-1H-pyrazole-4-carboxylic acid,
- 5-Ethyl-1-(quinolin-5-yl)-1H-pyrazole-4-carboxylic acid,
- 5-Cyclopropyl-1-(quinolin-5-yl)-1H-pyrazole-4-carboxylic acid or
- 1-(Isoquinolin-5-yl)-3-methyl-1H-pyrazole-4-carboxylic acid or a pharmaceutically acceptable salt of said compound.
14 more elements
A compound selected from the esters of
- 5-cyclopropyl-1-(2-trifluoromethylphenyl)-1H-pyrazole-4-carboxylate,
- 5-methyl-1-(6-quinolinyl)-1H-pyrazole-4-carboxylate,
- 5-methyl-1-naphthalenyl-1H-pyrazole-4-carboxylate,
- 5-cyclopropyl-1-(quinolin-8-yl)-1H-pyrazole-4-carboxylate,
- 5-cyclopropyl-1-(quinolin-5-yl)-1H-pyrazole-4-carboxylate,
- 5-ethyl-1-(quinolin-5-yl)-1H-pyrazole-4-carboxylate and
- 1-(isoquinolin-5-yl)-3-methyl-1H-pyrazole4-carboxylate wherein said esters are benzyl, (C1-C6)alkyl or (C4-C8)cycloalkyl, said (C4-C8)cycloalkyl optionally mono-substituted with (C1-C4)alkyl or a pharmaceutically acceptable salt of said compound.
4 more elements
A compound selected from
- 5-methyl-2-(5-quinolinyl)-2H-1,2,3-triazole-4-carboxylic acid,
- 5-methyl-2-(5-isoquinolinyl)-2H-1,2,3-triazole-4-carboxylic acid,
- 2-(1 -naphthalenyl)-5-methyl-2H-1,2,3-triazole-4-carboxylic acid,
- 5-methyl-1-(6-quinolinyl)-1H-pyrazole4-carboxylic acid,
- 5-methyl-1-naphthalenyl-1H-pyrazole4-carboxylic acid,
- 5-cyclopropyl-1-(quinolin-8-yl)-1H-pyrazole-4-carboxylic acid,
- 5-cyclopropyl-1-(2-trifluoromethylphenyl)-1H-pyrazole-4-carboxylic acid,
- 5-ethyl-1-(quinolin-5-yl)-1H-pyrazole-4-carboxylic acid,
- 5-cyclopropyl-1-(quinolin-5-yl)-1H-pyrazole4-carboxylic acid or
- 1-(isoquinolin-5-yl)-3-methyl-1H-pyrazole-4-carboxylic acid or the acid chlorides thereof or a pharmaceutically acceptable salt of said compounds or of said acid chlorides.
7 more elements
Dependencies are inferred from the claim text.